Increased vitreous levels of hydroimidazolone in type 2 diabetes patients are associated with retinopathy: A case-control study

Acta Ophthalmologica Scandinavica

Volumn 85, Issue 6, 2007, Pages 618-622

  Fosmark, Dag S ^a   Bragadóttir, Ragnheidur ^a   Stene Johansen, Ingar ^a   Berg, Jens P ^b   Berg, Tore J ^b   Lund, Terje ^b   Sandvik, Leiv ^a   Hanssen, Kristian F ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Advanced glycation endproducts; Blood retinal barrier; Diabetic retinopathy; Hydroimidazolone; VEGF; Vitreous

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; HEMOGLOBIN A1C; HYDROIMIDAZOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD RETINA BARRIER; CASE CONTROL STUDY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; EYE INJURY; FEMALE; HUMAN; IMMUNOASSAY; LOGISTIC REGRESSION ANALYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TISSUE LEVEL; VITRECTOMY; VITREOUS BODY;

EID: 34548203887     PISSN: 13953907     EISSN: 16000420     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2007.00913.x     Document Type: Article

References (20)

1. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK & Yeo KT (1994): Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118: 445-450.
2. Ahmed N, Thornalley PJ, Dawczynski J, Franke S, Strobel J, Stein G & Haik GM (2003): Methylglyoxal-derived hydroimidazolone advanced glycation endproducts of human lens proteins. Invest Ophthalmol Vis Sci 44: 5287-5292.
3. BednarMR & Bayer PM (1993): Correction: measurements of plasma haemoglobin. Clin Chem 39: 2027-2028.
4. Berg TJ, Dahl-Jorgensen K, Torjesen PA & Hanssen KF (1997): Increased serum levels of advanced glycation endproducts (AGEs) in children and adolescents with IDDM. Diabetes Care 20: 1006-1008.
5. Cunha-Vaz JG (1976): The blood-retinal barriers. Doc Ophthalmol 41: 287-327.
6. Deng J, Wu DZ & Gao R (1999): Elevated vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Yan Ke Xue Bao 15: 17-21.
7. Denis U, Lecomte M, Paget C, Ruggiero D, Wiernsperger N & Lagarde M (2002): Advanced glycation endproducts induce apoptosis of bovine retinal pericytes in culture: Involvement of diacylglycerol/ceramide production and oxidative stress induction. Free Radic Biol Med 33: 236-247.
8. Fairbanks VF, Ziesmer SC & O'Brien PC (1992): Methods for measuring plasma haemoglobin in micromolar concentration compared. Clin Chem 38: 132-140.
9. Fosmark DS, Torjesen PA, Kilhovd BK, Berg TJ, Sandvik L, Hanssen KF, Agardh CD & Agardh E (2006): Increased serum levels of the specific advanced glycation endproduct methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism 55: 232-236.
10. Hamada Y, Nakashima E, Naruse K et al. (2005): A copper chelating agent suppresses carbonyl stress in diabetic rat lenses. J Diabetes Complications 19: 328-334.
11. Harboe M (1959): A method for determination of haemoglobin in plasma by near-ultraviolet spectrophotometry. Scand J Clin Lab Invest 11: 66-70.
12. Karachalias N, Babaei-Jadidi R, Ahmed N & Thornalley PJ (2003): Accumulation of fructosyl-lysine and advanced glycation endproducts in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans 31: 1423-1425.
13. Kilhovd BK, Giardino I, Torjesen PA, Birkeland KI, Berg TJ, Thornalley PJ, Brownlee M & Hanssen KF (2003): Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 52: 163-167.
14. Klein R, Klein BE, Moss SE, Davis MD & DeMets DL (1988): Glycosylated haemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 260: 2864-2871.
15. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R & Adamis AP (1998): Advanced glycation endproducts increase retinal vascular endothelial growth factor expression. J Clin Invest 101: 1219-1224.
16. Moss SE, Klein R & Klein BE (1994): Ten-year incidence of visual loss in a diabetic population. Ophthalmology 101: 1061-1070.
17. Stitt AW, Frizzell N & Thorpe SR (2004): Advanced glycation and advanced lipoxidation: Possible role in initiation and progression of diabetic retinopathy. Curr Pharm Des 10: 3349-3360.
18. Turner RC, Hollman RR, Cull CA et al. (1998): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853.
19. Vinores SA, Derevjanik NL, Ozaki H, Okamoto N & Campochiaro PA (1999): Cellular mechanisms of blood-retinal barrier dysfunction in macular oedema. Doc Ophthalmol 97: 217-228.
20. Yokoi M, Yamagishi SI, Takeuchi M et al. (2005): Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br J Ophthalmol 89: 673-675.